ArticleStatistics in medicine2026
Multiple Summary Knowledge-Based Disease Prevalence Estimation for Group Testing Data.
Article in Statistics in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Group testing is widely recognized for its ability to reduce time and cost in screening for rare diseases. However, with limited samples, the parameter estimation from group-testing data might be inefficient. In some scenarios, the external summary statistics are available. To make full use of them, we propose a multiple-source knowledge transfer method. The resulting prevalence estimator is consistent and more efficient than the conventional estimator based on the target group-testing data alone. We establish the asymptotic normality of the proposed estimator. In addition, we develop a data-driven screening procedure to identify the transferable sources. We extend this framework to Dorfman's two-stage group testing design and show that integrating the retesting data yields efficiency gains. The asymptotic normality of the corresponding estimator is also established. Extensive simulations and a real-data application support the theoretical results and demonstrate the favorable finite-sample performance of the proposed method.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.